Prelude Therapeutics (PRLD) Short Interest Ratio & Short Volume → I’m afraid WWIII is a very real possibility (From Porter & Company) (Ad) Free PRLD Stock Alerts $4.00 -0.28 (-6.54%) (As of 05/17/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Prelude Therapeutics Short Interest DataCurrent Short Volume630,600 sharesPrevious Short Volume604,000 sharesChange Vs. Previous Month+4.40%Dollar Volume Sold Short$2.38 millionShort Interest Ratio / Days to Cover9.7Last Record DateApril 30, 2024Outstanding Shares42,080,000 sharesFloat Size25,920,000 sharesShort Percent of Float2.43%Today's Trading Volume40,740 sharesAverage Trading Volume61,517 sharesToday's Volume Vs. Average66% Short Selling Prelude Therapeutics ? Sign up to receive the latest short interest report for Prelude Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatPRLD Short Interest Over TimePRLD Days to Cover Over TimePRLD Percentage of Float Shorted Over Time Ad Weiss RatingsThe ONE AI Stock to own now. (It’s not Nvidia.)Don’t panic — you haven’t missed the boat on AI. In fact, it has barely launched. Sure, the early stages of this boom were big … But I believe the real wealth in AI has yet to be made …Click here to see the presentation now. Prelude Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/30/2024630,600 shares $2.38 million +4.4%2.4%9.7 $3.77 4/15/2024604,000 shares $3.40 million -2.9%1.8%8.8 $5.63 3/31/2024621,900 shares $2.95 million -3.3%1.8%9.1 $4.74 3/15/2024643,200 shares $3.05 million +3.9%1.9%8.7 $4.74 2/29/2024619,100 shares $2.66 million +22.9%2.3%4.7 $4.30 2/15/2024503,800 shares $1.75 million -3.5%1.8%3.4 $3.48 Get the Latest News and Ratings for PRLD and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Prelude Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 1/31/2024522,000 shares $1.71 million +15.6%1.8%3.7 $3.28 1/15/2024451,500 shares $1.71 million +1.0%1.6%2.2 $3.78 12/31/2023446,900 shares $1.91 million -34.3%1.5%2.1 $4.27 12/15/2023680,100 shares $2.96 million -8.2%2.3%3.2 $4.35 11/30/2023741,000 shares $2.45 million -7.9%2.6%4 $3.31 11/15/2023804,400 shares $2.73 million +0.6%2.8%4.9 $3.39 10/31/2023799,900 shares $1.35 million +0.1%3.2%4.8 $1.69 10/15/2023798,800 shares $1.93 million -58.4%3.2%8.1 $2.42 9/30/20231,920,000 shares $5.93 million +10.3%7.6%17.9 $3.09 9/15/20231,740,000 shares $5.53 million +1.2%6.9%16.6 $3.18 8/31/20231,720,000 shares $6.42 million -19.6%7.1%14.8 $3.73 8/15/20232,140,000 shares $8.07 million +0.5%8.9%18.9 $3.77 7/31/20232,130,000 shares $8.33 million -20.5%8.3%17.6 $3.91 7/15/20232,680,000 shares $11.68 million -5.0%11.0%22.5 $4.36 6/30/20232,820,000 shares $12.69 million +6.4%12.8%23.9 $4.50 6/15/20232,650,000 shares $14.02 million +3.9%10.4%21.6 $5.29 5/31/20232,550,000 shares $14.23 million -3.0%9.5%24.2 $5.58 5/15/20232,630,000 shares $17.46 million -1.5%12.4%26.9 $6.64 4/30/20232,670,000 shares $17.25 million +5.5%7.8%34.9 $6.46 4/15/20232,530,000 shares $20.54 million +26.5%7.4%31.6 $8.12 3/31/20232,000,000 shares $11.40 million +9.3%6.7%25.3 $5.70 3/15/20231,830,000 shares $11.93 million +3.4%6.1%27.7 $6.52 2/28/20231,770,000 shares $10.02 million +9.3%7.8%22.4 $5.66 2/15/20231,620,000 shares $9.37 million +5.9%7.1%20.9 $5.79 1/31/20231,530,000 shares $9.76 million +3.4%8.9%18.3 $6.38 1/15/20231,480,000 shares $8.89 million +1.4%8.6%18.1 $6.01 12/30/20221,460,000 shares $8.82 million -13.1%8.5%18.2 $6.04 12/15/20221,680,000 shares $8.74 million -5.6%9.8%22 $5.20 11/30/20221,780,000 shares $11.87 million +0.6%10.4%23.8 $6.67 11/15/20221,770,000 shares $13.81 million -11.5%10.3%27.4 $7.80 10/31/20222,000,000 shares $13.38 million -3.4%8.8%29.7 $6.69 10/15/20222,070,000 shares $13.60 million -13.0%12.3%27.5 $6.57 9/30/20222,380,000 shares $15.73 million -3.6%14.1%27.4 $6.61 9/15/20222,470,000 shares $18.57 million -3.5%9.5%21.4 $7.52He called Apple at $1.49 and now he says: “Buy these 6 AI stocks.” (Ad)For over four decades, Louis Navellier has found the very best tech stocks... Before the rest of the market.Click for his six specific AI stock in the crosshairs PRLD Short Interest - Frequently Asked Questions What is Prelude Therapeutics' current short interest? Short interest is the volume of Prelude Therapeutics shares that have been sold short but have not yet been covered or closed out. As of April 30th, traders have sold 630,600 shares of PRLD short. 2.43% of Prelude Therapeutics' shares are currently sold short. Learn More on Prelude Therapeutics' current short interest. What is a good short interest ratio for Prelude Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. PRLD shares currently have a short interest ratio of 10.0. Learn More on Prelude Therapeutics's short interest ratio. What is a good short interest percentage for Prelude Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 2.43% of Prelude Therapeutics' floating shares are currently sold short. Is Prelude Therapeutics' short interest increasing or decreasing? Prelude Therapeutics saw a increase in short interest in April. As of April 30th, there was short interest totaling 630,600 shares, an increase of 4.4% from the previous total of 604,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Prelude Therapeutics' float size? Prelude Therapeutics currently has issued a total of 42,080,000 shares. Some of Prelude Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Prelude Therapeutics currently has a public float of 25,920,000 shares. How does Prelude Therapeutics' short interest compare to its competitors? 2.43% of Prelude Therapeutics' shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to Prelude Therapeutics: scPharmaceuticals Inc. (17.76%), ProQR Therapeutics (0.41%), Capricor Therapeutics Inc (13.01%), Gossamer Bio, Inc. (5.68%), Rigel Pharmaceuticals, Inc. (3.23%), Repare Therapeutics Inc. (2.38%), Alimera Sciences, Inc. (0.23%), CervoMed Inc. (1.06%), CytomX Therapeutics, Inc. (4.62%), Skye Bioscience, Inc. (0.29%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.98 billion), Occidental Petroleum Co. ($3.35 billion), Charter Communications, Inc. ($3.06 billion), General Motors ($2.88 billion), Moderna, Inc. ($2.32 billion), Tractor Supply ($2.27 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.18 billion), Williams-Sonoma, Inc. ($1.95 billion), and Chesapeake Energy Co. ($1.52 billion). View all of the most shorted stocks. What does it mean to sell short Prelude Therapeutics stock? Short selling PRLD is an investing strategy that aims to generate trading profit from Prelude Therapeutics as its price is falling. PRLD shares are trading down $0.28 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Prelude Therapeutics? A short squeeze for Prelude Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of PRLD, which in turn drives the price of the stock up even further. How often is Prelude Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including PRLD, twice per month. The most recent reporting period available is April, 30 2024. More Short Interest Resources from MarketBeat Related Companies: scPharmaceuticals Short Interest ProQR Therapeutics Short Interest Capricor Therapeutics Short Interest Gossamer Bio Short Interest Rigel Pharmaceuticals Short Interest Repare Therapeutics Short Interest Alimera Sciences Short Interest CervoMed Short Interest CytomX Therapeutics Short Interest Skye Bioscience Short Interest Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:PRLD) was last updated on 5/18/2024 by MarketBeat.com Staff From Our PartnersThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingA letter is coming from the "Bureau of the Fiscal Service".Stansberry ResearchElon’s New Device is About to Shock the WorldInvestorPlaceMake this ONE trade on Tuesday at 2 p.m. EST!Monument Traders Alliance[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressHe Is Giving Away BitcoinCrypto Swap Profits